Recent Updates
Recently added Catalysts
PLSE Positive Sentiment

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Friday, October 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Pulse Biosciences, Inc. has granted equity inducement awards to two new employees as part of its 2017 Inducement Equity Incentive Plan. This move is outside of the existing 2017 Equity Incentive Plan, indicating the company's strategy to attract talent while leveraging its proprietary Nanosecond Pulsed Field Ablation technology. The announcement reflects the company's ongoing commitment to growth and innovation.

Market Sentiment Analysis

POSITIVE FACTORS

  • Pulse Biosciences is expanding its team with new hires.
  • The company is utilizing its innovative nano-PFA technology.
  • Equity inducement awards reflect confidence in future growth.

Full Press Release Details

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to two new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were appr

Frequently Asked Questions

What are the inducement grants announced by Pulse Biosciences?

Pulse Biosciences announced equity inducement awards for two new employees.

Under which plan were the inducement grants made?

The grants were made under the 2017 Inducement Equity Incentive Plan.

What technology does Pulse Biosciences utilize?

The company leverages its proprietary Nanosecond Pulsed Field Ablation technology.

What does Nasdaq Listing Rule 5635(c)(4) pertain to?

It relates to the granting of equity awards to attract new employees.

ShareAdd on Google
Tags: PLSE Pulse Biosciences equity awards nanosecond pulsed field ablation inducement grants
Last updated: Oct 9, 2026

Biotech snapshot

Cash runway
$102M liquidity · $6M/mo burn
~14 mo
Low dilution risk